Insys Therapeutics (INSY) Gross Profit Margin starting from the first quarter 2019 to first quarter 2018, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Insys Therapeutics, Inc.  (INSY)


Insys Therapeutics's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

INSY Gross Profit Margin (Mar 31 2019)
Q1 		(Dec 31 2018)
Q4 		(Sep 30 2018)
Q3 		(Jun 30 2018)
Q2 		(Mar 31 2018)
Q1
Y / Y Revenue Change -68.09 %
Seq. Revenue Change -53.35 %
Revenue In Millions $7.63
Gross Profit Margin 40.04 %
Gross Profit Margin Total Ranking # 2350
Gross Profit In Millions $3.06
Y / Y Gross Profit Change -85.93 %
Seq. Gross Profit Change -77.75 %


Commenting First Quarter 2019 Gross Profit Margin
Insys Therapeutics, Inc. experienced contraction in Gross Profit by -77.75 % to $8 millions and Revenue by -53.35 %, while Gross Profit Margin fell to 40.04 %, below company*s average Gross Profit Margin.


Observing first quarter 2019 results within Major Pharmaceutical Preparations industry 137 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin overall ranking has deteriorated relative to the three months before, from 437 to 2350.
Learn about Gross Margin
INSY's Gross Profit Margin first quarter 2019 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 138
Healthcare Sector # 373
Overall # 2279

Gross Profit Margin Statistics
High Average Low
95.13 % 82.14 % 0.09 %
(Mar 31 2015)   (Dec 31 2014)


INSY Gross Income Trends • More of INSY's Profitabilty Ratios • INSY Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
INSY's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
INSY's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for INSY's Competitors
Gross Profit Margin Profit Margin for Insys Therapeutics's Suppliers
Gross Profit Margin Profit Margin for INSY's Customers

You may also want to know
INSY's Annual Growth Rates INSY's Profitability Ratios INSY's Asset Turnover Ratio INSY's Dividend Growth
INSY's Roe INSY's Valuation Ratios INSY's Financial Strength Ratios INSY's Gross Profit Growth
INSY's Roa INSY's Inventory Turnover Ratio INSY's Growth Rates INSY's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Mar 31 2019, within Major Pharmaceutical Preparations Industry Gross Profit MarginMar 31 2019 MRQ Gross ProfitMar 31 2019 MRQ Revenue
Ionis Pharmaceuticals Inc   99.65 %$ 296.173  Millions$ 297.214  Millions
Omeros Corporation  99.40 %$ 21.648  Millions$ 21.779  Millions
American Brivision (holding) Corp  99.29 %$ 0.211  Millions$ 0.212  Millions
Rigel Pharmaceuticals Inc  99.15 %$ 12.517  Millions$ 12.624  Millions
Intercept Pharmaceuticals inc   98.90 %$ 51.678  Millions$ 52.252  Millions
Agios Pharmaceuticals Inc   98.90 %$ 29.893  Millions$ 30.227  Millions
Sangui Biotech International Inc  98.77 %$ 0.008  Millions$ 0.008  Millions
Akcea Therapeutics Inc   98.51 %$ 161.372  Millions$ 163.816  Millions
Ironwood Pharmaceuticals inc   98.48 %$ 67.687  Millions$ 68.730  Millions
Stemline Therapeutics Inc  98.30 %$ 4.963  Millions$ 5.049  Millions
Corcept Therapeutics Inc  98.09 %$ 63.589  Millions$ 64.829  Millions
Ultragenyx Pharmaceutical Inc   97.51 %$ 17.720  Millions$ 18.172  Millions
Travere Therapeutics Inc   97.43 %$ 38.553  Millions$ 39.570  Millions
Bellicum Pharmaceuticals Inc   96.76 %$ 0.896  Millions$ 0.926  Millions
Celgene Corp  96.52 %$ 3,885.000  Millions$ 4,025.000  Millions
Adamas Pharmaceuticals Inc  96.46 %$ 11.252  Millions$ 11.665  Millions
Regeneron Pharmaceuticals Inc   95.86 %$ 1,640.900  Millions$ 1,711.800  Millions
Supernus Pharmaceuticals inc   95.69 %$ 81.790  Millions$ 85.474  Millions
Ptc Therapeutics inc   95.57 %$ 51.207  Millions$ 53.583  Millions
Assertio Holdings inc   95.55 %$ 55.354  Millions$ 57.929  Millions
Skinvisible Inc   95.51 %$ 0.008  Millions$ 0.008  Millions
Acadia Pharmaceuticals Inc   95.31 %$ 60.009  Millions$ 62.959  Millions
Intelgenx Technologies Corp   94.23 %$ 0.392  Millions$ 0.416  Millions
Lexicon Pharmaceuticals Inc   94.00 %$ 8.663  Millions$ 9.216  Millions
Alexion Pharmaceuticals Inc   92.48 %$ 1,054.600  Millions$ 1,140.400  Millions
United Therapeutics Corporation  91.97 %$ 333.500  Millions$ 362.600  Millions
Puma Biotechnology Inc   91.94 %$ 91.082  Millions$ 99.067  Millions
Oramed Pharmaceuticals Inc  91.74 %$ 0.611  Millions$ 0.666  Millions
Zyla Life Sciences  91.42 %$ 5.724  Millions$ 6.261  Millions
Siga Technologies Inc  91.25 %$ 9.544  Millions$ 10.459  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.